Our DecisionDx molecular tests provide tumor-specific information for better decision-making and patient care
We discover, develop, commercialize and secure coverage for practice-changing tests
ASCO 2016: Studies confirm DecisionDx-Melanoma as recurrence predictor independent of, additive to standard staging factors (>97% NPV for MSS)
Our genomic test was found to identify metastatic risk in Stage 1 & 2 melanoma independent of sentinel lymph node biopsy status and other traditional staging factors.
This gene expression profile test quickly became standard of care based on its ability to accurately identify aggressive metastatic disease in this rare and deadly eye cancer.
ALEXANDRIA, Va. and SANTA CLARA, Calif. and FRIENDSWOOD, Texas.– May 9, 2017 – Oxford Finance LLC (“Oxford”), a specialty finance ...
Friendswood, TX – May 1, 2017 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, ...